Zymeworks BC Inc (NASDAQ: ZYME) is 31.86% higher on its value in year-to-date trading and has touched a low of $6.79 and a high of $14.05 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZYME stock was last observed hovering at around $13.87 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $13.70, the stock is 3.86% and 9.27% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.69 million and changing -1.23% at the moment leaves the stock 29.46% off its SMA200. ZYME registered 95.16% gain for a year compared to 6-month gain of 52.22%. The firm has a 50-day simple moving average (SMA 50) of $12.5378 and a 200-day simple moving average (SMA200) of $10.582175.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 10.57% loss in the last 1 month and extending the period to 3 months gives it a 34.31%, and is 6.04% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.02% over the week and 3.00% over the month.
Zymeworks BC Inc (ZYME) has around 277 employees, a market worth around $1.18B and $62.71M in sales. Profit margin for the company is -179.42%. Distance from 52-week low is 101.77% and -2.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.57%).
Zymeworks BC Inc quarterly earnings per share for the current quarter are estimated at -0.4 with sales reaching $15.3M over the same period.The EPS is expected to grow by 32.27% this year, but quarterly earnings will post 38.70% year-over-year. Quarterly sales are estimated to shrink -7.30% in year-over-year returns.
230.0 institutions hold shares in Zymeworks BC Inc (ZYME), with institutional investors hold 101.03% of the company’s shares. The shares outstanding are 86.45M, and float is at 84.22M with Short Float at 4.94%. Institutions hold 100.95% of the Float.
Zymeworks BC Inc (ZYME) Insider Activity
The most recent transaction is an insider sale by Galbraith Kenneth, the company’s Chair & CEO. SEC filings show that Galbraith Kenneth sold 18,198 shares of the company’s common stock on Jan 05 ’24 at a price of $10.65 per share for a total of $0.19 million. Following the sale, the insider now owns 29468.0 shares.
Zymeworks BC Inc disclosed in a document filed with the SEC on Jan 08 ’24 that Galbraith Kenneth (Chair & CEO) sold a total of 5,706 shares of the company’s common stock. The trade occurred on Jan 08 ’24 and was made at $11.22 per share for $63996.0. Following the transaction, the insider now directly holds 23762.0 shares of the ZYME stock.
Still, SEC filings show that on Jan 05 ’24, Astle Christopher (SVP & Chief Financial Officer) disposed off 4,563 shares at an average price of $10.65 for $48606.0. The insider now directly holds 7,934 shares of Zymeworks BC Inc (ZYME).
